Neutropenia

• 

  Subject Areas on Research

  • 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. 
  • 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. 
  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. 
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. 
  • A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. 
  • A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. 
  • A cost analysis of hematopoietic colony-stimulating factors. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. 
  • A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. 
  • A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. 
  • A pilot study comparing the neutropenic diet to a non-neutropenic diet in the allogeneic hematopoietic stem cell transplantation population. 
  • A predictive model for neutropenia associated with cancer chemotherapy. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. 
  • A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. 
  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 
  • A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. 
  • A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Aerosolized antifungal prophylaxis: the winds of change? 
  • Agents under investigation for the treatment and prevention of neutropenia. 
  • Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. 
  • An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). 
  • Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. 
  • Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 
  • Antibodies to granulocyte precursors in selective myeloid hypoplasia and other suspected autoimmune neutropenias: use of HL-60 cells as targets. 
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 
  • Are we finally ready for outpatient management of febrile neutropenia? 
  • Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. 
  • Balancing the benefits and costs of colony-stimulating factors: a current perspective. 
  • Biosimilars: are they ready for primetime in the United States? 
  • Breakthrough invasive fungal infections: Who is at risk? 
  • Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity. 
  • Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia. 
  • Chemotherapy dose intensity and quality cancer care. 
  • Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. 
  • Colony stimulating factors for chemotherapy induced febrile neutropenia. 
  • Colony-stimulating factor use in the context of refined risk and benefit assessments. 
  • Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. 
  • Colony-stimulating factors: clinical applications. 
  • Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. 
  • Cost effectiveness of myeloid growth factors in cancer chemotherapy. 
  • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. 
  • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. 
  • Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. 
  • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. 
  • Costs associated with febrile neutropenia in the US. 
  • Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. 
  • Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. 
  • Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. 
  • Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. 
  • Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms. 
  • Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. 
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. 
  • Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. 
  • Dyshematopoiesis in combined immune deficiency with congenital neutropenia. 
  • Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. 
  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. 
  • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. 
  • Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. 
  • Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. 
  • Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 
  • Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia. 
  • Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy. 
  • Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. 
  • Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. 
  • Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias. 
  • Enterococcus species and the central line-associated bloodstream infection surveillance definition: evaluating the importance of blood culture contamination. 
  • Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm. 
  • Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. 
  • Evidence-based use of colony-stimulating factors in elderly cancer patients. 
  • Fatal, disseminated Acremonium strictum infection in a neutropenic host. 
  • Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. 
  • Filgrastim in patients with neutropenia: potential effects on quality of life. 
  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. 
  • G-CSF as prophylaxis of febrile neutropenia in SCLC. 
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Granulocyte colony-stimulating factors: finding the right indication. 
  • Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 
  • Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. 
  • Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. 
  • Hematopoietic growth factors: ESMO recommendations for the applications. 
  • Hemopoietic reserve in the older cancer patient: clinical and economic considerations. 
  • Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia. 
  • High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. 
  • Hyper IgM Syndrome: a Report from the USIDNET Registry. 
  • Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. 
  • Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. 
  • Impact of chemotherapy dose intensity on cancer patient outcomes. 
  • Impact of neutropenia on clinical manifestations and outcome of Staphylococcus aureus bloodstream infection: a propensity score-based overlap weight analysis in two large, prospectively evaluated cohorts. 
  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. 
  • Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. 
  • Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. 
  • Improving the management of chemotherapy-induced neutropenia. 
  • Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. 
  • Infectious and bleeding complications in patients with glycogenosis Ib. 
  • Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism. 
  • Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • Interactive discussion on chemotherapy-related adverse events. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) 
  • Introduction. Neutropenia risk models in oncology. 
  • Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia. 
  • Key Pathogenic Factors in Coronavirus Disease 2019-Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. 
  • Length of stay and mortality associated with febrile neutropenia among children with cancer. 
  • Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. 
  • Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. 
  • Liver transplantation for glycogen storage disease types I, III, and IV. 
  • Long-term outcomes of myeloid growth factor treatment. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. 
  • Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. 
  • Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. 
  • Mortality rates in comparative trials of formulations of amphotericin B. 
  • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. 
  • Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. 
  • Myeloid growth factors clinical practice guidelines in oncology. 
  • Myeloid growth factors. 
  • Myeloid growth factors. 
  • Myeloid growth factors. 
  • Myeloid growth factors. Clinical practice guidelines in oncology. 
  • Myeloid-Specific Deletion of Mcl-1 Yields Severely Neutropenic Mice That Survive and Breed in Homozygous Form. 
  • Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. 
  • Myelotoxicity from chemotherapy. 
  • Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. 
  • Neuroleptic-induced neutropenia in the elderly. 
  • Neutropenia Precautions for Children Receiving Chemotherapy or Stem Cell Transplantation for Cancer. 
  • Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. 
  • Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. 
  • Neutrophil growth factors. 
  • Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. 
  • Opportunistic fungal pneumonia. 
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. 
  • Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. 
  • Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. 
  • Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. 
  • Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. 
  • Pegfilgrastim: the promise of pegylation fulfilled. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. 
  • Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. 
  • Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. 
  • Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. 
  • Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. 
  • Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. 
  • Predicting the risk of bacteremia in childen with fever and neutropenia. 
  • Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. 
  • Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. 
  • Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. 
  • Prevention and treatment of chemotherapy-induced neutropenia. 
  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. 
  • Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. 
  • Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. 
  • Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? 
  • Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials. 
  • Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 
  • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. 
  • Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. 
  • Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor. 
  • Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). 
  • Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 
  • Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. 
  • Risk assessment in oncology clinical practice. From risk factors to risk models. 
  • Risk models for predicting chemotherapy-induced neutropenia. 
  • Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. 
  • Risk of mortality in patients with cancer who experience febrile neutropenia. 
  • Risks and consequences of chemotherapy-induced neutropenia. 
  • Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. 
  • Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. 
  • Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. 
  • Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Selective antimicrobial modulation of human microbial flora. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy. 
  • Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. 
  • Significance of Clostridium tertium bacteremia in neutropenic and nonneutropenic patients: review of 32 cases. 
  • Staphylococcus aureus bacteremia in patients with neutropenia. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The colony-stimulating factors: use to prevent and treat neutropenia and its complications. 
  • The economics of febrile neutropenia: implications for the use of colony-stimulating factors. 
  • The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. 
  • The impact of the host on fungal infections. 
  • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. 
  • The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. 
  • The use of G-CSF during craniospinal irradiation. 
  • The use of an intrathecal pump to manage intractable cancer pain in a pediatric patient: a case report. 
  • Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. 
  • Thromboembolism in hospitalized neutropenic cancer patients. 
  • Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. 
  • Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 
  • Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient-Addendum to the Genotype-Phenotype Puzzle. 
  • Update on neutropenia and myeloid growth factors. 
  • Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. 
  • Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. 
  • Use of re-randomized data in meta-analysis. 
  • Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. 
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. 
  • Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • Withholding antibiotics from patients with febrile neutropenia. 
  • Zidovudine-induced neutropenia: are we too cautious? 
  • [Malignant melanoma: hepatic intra-arterial chemotherapy]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology